Encorafenib Combination Improves Responses in BRAF V600E-Mutant CRC
Scott Kopetz, MD, PhD, discusses the results of the phase III BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium.
Scott Kopetz, MD, PhD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the results of the phase III BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium.
The trial, which evaluated encorafenib (Braftovi) plus cetuximab (Erbitux) with or without binimetinib (Mektovi) in patients with BRAF V600E-mutant metastatic colorectal cancer (CRC), met its primary end point. Both experimental arms had a higher response rate compared with the standard of care. The response rate was 26% with the triplet combination, 20% with the doublet, and 2% in the control arm, Kopetz says.
The BEACON CRC trial led to the question of how treatment with encorafenib plus cetuximab with/without binimetinib will impact the quality of life in patients with BRAF V600E-mutant CRC. The presentation of these data at the 2020 GI Cancers Symposium focused on the question of how these results can impact the treatment of patients.
